# Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants

> **NCT06753955** · PHASE1 · COMPLETED · sponsor: **Arialys Therapeutics** · enrollment: 7 (actual)

## Conditions studied

- Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody
- Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)
- Autoimmune Encephalitis

## Interventions

- **DRUG:** ART5803
- **DRUG:** Intravenous immunoglobulin (IVIG)

## Key facts

- **NCT ID:** NCT06753955
- **Lead sponsor:** Arialys Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-25
- **Primary completion:** 2025-07-02
- **Final completion:** 2025-08-19
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06753955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06753955, "Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06753955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*